Home
/
Oncotelic Therapeutics, Inc.
/
Financials
/
Quarterly
Oncotelic Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Oncotelic Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2023
$70.0K
Nov 19, 2024
Q3
2021
Sep 30, 2020
$1.74M
Nov 22, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2021
Sep 30, 2020
$1.74M
Nov 22, 2021
Q2
2021
Jun 30, 2020
$1.40M
Aug 20, 2021
Q1
2021
Mar 31, 2020
$340.9K
May 24, 2021
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2014
Sep 30, 2013
$95.0K
Nov 13, 2014
Q3
2013
Sep 30, 2012
$114.0K
Nov 13, 2013
Q2
2013
Jun 30, 2012
$114.0K
Oct 18, 2013
Q1
2013
Mar 31, 2012
$114.0K
May 9, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.05M)
Nov 17, 2025
Q2
2025
Jun 30, 2025
$277.9K
Aug 13, 2025
Q1
2025
Mar 31, 2025
($298.7K)
May 15, 2025
Q3
2025
Sep 30, 2024
($3.30M)
Nov 17, 2025
Q2
2025
Jun 30, 2024
($209.8K)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($408.7K)
May 15, 2025
Q3
2024
Sep 30, 2023
$115.3K
Nov 19, 2024
Q2
2024
Jun 30, 2023
($6.76M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($525.4K)
May 15, 2024
Q3
2023
Sep 30, 2022
($777.9K)
Nov 14, 2023
Q2
2023
Jun 30, 2022
$16.01M
Aug 18, 2023
Q1
2023
Mar 31, 2022
($4.85M)
May 22, 2023
Q3
2022
Sep 30, 2021
($1.56M)
Nov 18, 2022
Q2
2022
Jun 30, 2021
($3.23M)
Aug 22, 2022
Q1
2022
Mar 31, 2021
($2.80M)
May 23, 2022
Q3
2021
Sep 30, 2020
($1.99M)
Nov 22, 2021
Q2
2021
Jun 30, 2020
$582.1K
Aug 20, 2021
Q3
2020
Jun 30, 2020
$582.1K
Nov 16, 2020
Q3
2020
Mar 31, 2020
($4.66M)
Nov 16, 2020
Q1
2021
Mar 31, 2020
($4.66M)
May 24, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($491.0K)
Nov 17, 2025
Q2
2025
Jun 30, 2025
($66.0K)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($101.1K)
May 15, 2025
Q3
2025
Sep 30, 2024
($3.28M)
Nov 17, 2025
Q2
2025
Jun 30, 2024
($96.6K)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($167.2K)
May 15, 2025
Q3
2024
Sep 30, 2023
$14.5K
Nov 19, 2024
Q2
2024
Jun 30, 2023
($6.32M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($264.1K)
May 15, 2024
Q3
2023
Sep 30, 2022
($595.4K)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($256.3K)
Aug 18, 2023
Q1
2023
Mar 31, 2022
($4.34M)
May 22, 2023
Q3
2022
Sep 30, 2021
($1.81M)
Nov 18, 2022
Q2
2022
Jun 30, 2021
($3.76M)
Aug 22, 2022
Q1
2022
Mar 31, 2021
($2.04M)
May 23, 2022
Q3
2021
Sep 30, 2020
($1.62M)
Nov 22, 2021
Q2
2021
Jun 30, 2020
$13.8K
Aug 20, 2021
Q1
2021
Mar 31, 2020
($2.65M)
May 24, 2021
Q3
2020
Sep 30, 2019
($930.7K)
Nov 16, 2020
Q2
2020
Jun 30, 2019
($1.16M)
Aug 14, 2020